CompletedNCT01041274
Citalopram added to treatment for depression in first-episode schizophrenia
About this title
Read the official source — NCT01041274Medication studyAges 16–40United States
Understand this study
Who was this study for?
Listed age limits: 16 years to 40 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: January 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 95
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Behavioural, Drug, Radiation
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 16 Years to 40 Years
- Official registry ID
- NCT01041274
- Official title
Show the full official title
Citalopram in First Episode Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is NYU Langone Health.
Did this study involve medication?
Yes. The study involved medication, including Citalopram and Placebo.
Who was this study for?
Listed age limits: 16 years to 40 years.
